ATE332364T1 - Verfahren zur gewinnung von purifizierter virenzuammensetzung - Google Patents

Verfahren zur gewinnung von purifizierter virenzuammensetzung

Info

Publication number
ATE332364T1
ATE332364T1 AT00906444T AT00906444T ATE332364T1 AT E332364 T1 ATE332364 T1 AT E332364T1 AT 00906444 T AT00906444 T AT 00906444T AT 00906444 T AT00906444 T AT 00906444T AT E332364 T1 ATE332364 T1 AT E332364T1
Authority
AT
Austria
Prior art keywords
purified virus
virus composition
obtaining purified
viral
particles
Prior art date
Application number
AT00906444T
Other languages
English (en)
Inventor
Michel Koehl
David Gaillac
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE332364T1 publication Critical patent/ATE332364T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00906444T 1999-02-22 2000-02-21 Verfahren zur gewinnung von purifizierter virenzuammensetzung ATE332364T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9902167 1999-02-22

Publications (1)

Publication Number Publication Date
ATE332364T1 true ATE332364T1 (de) 2006-07-15

Family

ID=9542357

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00906444T ATE332364T1 (de) 1999-02-22 2000-02-21 Verfahren zur gewinnung von purifizierter virenzuammensetzung

Country Status (8)

Country Link
US (1) US7264958B1 (de)
EP (1) EP1155120B1 (de)
JP (2) JP4802366B2 (de)
AT (1) ATE332364T1 (de)
AU (1) AU774437B2 (de)
CA (1) CA2364934C (de)
DE (1) DE60029195T2 (de)
WO (1) WO2000050573A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1073721B1 (de) 1998-04-22 2005-08-31 Genvec, Inc. Effiziente reinigung von adenovirus
US7056723B2 (en) * 2001-12-20 2006-06-06 Bavarian Nordic A/S Method for the recovery and purification of poxviruses from infected cells
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
ES2329607T3 (es) 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
US8574595B2 (en) 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
JP4670583B2 (ja) * 2005-10-20 2011-04-13 チッソ株式会社 水溶性カチオン性磁気微粒子を用いた脂質ベシクルの分離又は検出方法
EP2043767B1 (de) 2006-07-14 2020-03-25 Wisconsin Alumni Research Foundation Adsorptionsmembranen zum einfangen von viren
PE20081723A1 (es) 2007-01-30 2008-12-14 Transgene Sa Vacuna contra el papilomavirus
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
MX2011007386A (es) 2009-01-20 2011-08-03 Transgene Sa Icam-1 soluble como un biomarcador para la prediccion de una respuesta terapeutica.
WO2010108908A1 (en) 2009-03-24 2010-09-30 Transgene Sa Biomarker for monitoring patients
JP5661738B2 (ja) 2009-04-17 2015-01-28 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． 患者をモニターするためのバイオマーカー
CA2767458A1 (en) 2009-07-10 2011-01-13 Bruce Acres Biomarker for selecting patients and related methods
BR112012002628B1 (pt) 2009-08-07 2021-09-08 Transgene Sa Composição imunogênica, molécula de ácido nucleico, vetor, partícula viral infecciosa, micro-organismo transgênico, composição, usos da composição imunogênica e kit de partes
KR101820980B1 (ko) 2010-02-15 2018-01-22 얀센 백신스 앤드 프리벤션 비.브이. Ａｄ 26 아데노바이러스 벡터를 제조하는 방법
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
EP2632562B1 (de) * 2010-10-27 2020-08-05 Philip Morris Products S.a.s. Verfahren zur erfassung virusähnlicher partikel aus pflanzen unter verwendung von expansionsbett- chromatografie
CN105821078A (zh) 2010-12-09 2016-08-03 巴斯德研究所 用于获得高产量重组蛋白表达的基于mgmt的方法
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
WO2013045658A1 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
WO2014009438A2 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterial antigen vaccine
EP3587455A1 (de) 2012-10-23 2020-01-01 Emory University Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
CN112516179A (zh) 2013-06-14 2021-03-19 普赛奥克苏斯治疗公司 用于b型腺病毒的给药方案及制剂
SG11201602887QA (en) 2013-10-25 2016-05-30 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
US10765731B2 (en) 2014-01-09 2020-09-08 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
EA201891022A1 (ru) 2015-12-17 2019-01-31 Псайоксус Терапьютикс Лимитед Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
CN109477074B (zh) 2016-02-19 2023-01-24 威斯康星旧生研究基金会 用于疫苗开发的改进的乙型流感病毒复制
EP3452081A1 (de) 2016-05-04 2019-03-13 Transgene SA Kombinationstherapie mit cpg-tlr9-liganden
MY197324A (en) 2016-08-29 2023-06-13 Akamis Bio Ltd Adenovirus armed with bispecific t cell activator
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
EP3522920A2 (de) 2016-10-10 2019-08-14 Transgene SA Immuntherapeutisches produkt und mdsc-modulator-kombinationstherapie
US11826423B2 (en) 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
US11203629B2 (en) 2017-04-22 2021-12-21 Immunomic Therapeutics, Inc. LAMP constructs
CA3061950A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
EP3793595A1 (de) 2018-05-15 2021-03-24 Immunomic Therapeutics, Inc. Verbesserte lamp-konstrukte mit allergenen
JP7783047B2 (ja) * 2018-08-07 2025-12-09 ウィスコンシン アルムニ リサーチ ファンデイション 組換えの生物学的に封じ込められたフィロウイルスワクチン
EP3840780A1 (de) 2018-08-20 2021-06-30 Wisconsin Alumni Research Foundation Vektoren zur auslösung von immunantworten auf nicht-dominante epitope im hämagglutinin (ha)-protein
EP3833398A4 (de) 2018-09-21 2021-12-22 University of Connecticut Zusammensetzungen und verfahren zur wiederherstellung der paternalen ube3a-genexpression bei angelman-syndrom beim menschen
JP2022507920A (ja) * 2018-11-22 2022-01-18 フィクスド ファージ リミテッド 固定化バクテリオファージの生産
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
GB201909081D0 (en) * 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
JP7627911B2 (ja) 2019-08-27 2025-02-07 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
JP2022551732A (ja) 2019-10-18 2022-12-13 イミュノミック セラピューティックス， インコーポレイテッド がん抗原を含む改良ｌａｍｐ構築物
CN114980920A (zh) 2019-11-18 2022-08-30 詹森生物科技公司 基于突变体calr和jak2的疫苗及其用途
EP4093415A1 (de) 2020-01-24 2022-11-30 Wisconsin Alumni Research Foundation (WARF) Rekombinante influenza-viren mit stabilisiertem na
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
EP4135757A1 (de) 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma- und steap1-impfstoffe und ihre verwendungen
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009051A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
US20230241530A1 (en) * 2022-02-01 2023-08-03 W. L. Gore & Associates, Inc. Affinity chromatography devices containing a heat treated fibrillated polymer membrane for the separation of mrna and viral vectors from an aqueous mixture
CA3247515A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructions comprising genes that enhance the immune response and methods of their use
WO2025158316A1 (en) 2024-01-26 2025-07-31 Janssen Biotech, Inc. Ovarian neoantigens and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0328256A1 (de) * 1988-01-21 1989-08-16 Owens-Corning Fiberglas Corporation Glasfaser, überzogen mit Agarose, zur Verwendung als Säulenpackung oder chromatographisches Medium in Biotrennungen
GB8806605D0 (en) * 1988-03-19 1988-04-20 Robinson E Composite adsorbents
SE9101149D0 (sv) 1991-04-17 1991-04-17 Pharmacia Lkb Biotech Beads for down stream processing
DE4128953A1 (de) * 1991-08-30 1993-03-04 Basf Ag Verfahren zur kultivierung von saeugerzellen im fliessbettreaktor
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
FR2737730B1 (fr) * 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
AU722196B2 (en) * 1995-08-30 2000-07-27 Genzyme Corporation Chromatographic purification of adenovirus and AAV
AU2660397A (en) * 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
CZ438398A3 (cs) 1996-07-01 1999-03-17 Rhone-Poulenc Rorer S. A. Způsob přípravy rekombinantních adenovirů
WO1998022588A2 (en) 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
ATE353956T1 (de) 1996-12-13 2007-03-15 Schering Corp Methoden zur virus-reinigung
SE9700383D0 (sv) * 1997-02-04 1997-02-04 Pharmacia Biotech Ab An adsorption/separation method and a medium for adsorption/separation
AU2583099A (en) 1998-02-04 1999-08-23 Sun Microsystems, Inc. Method and apparatus for efficient authentication and integrity checking using hierarchical hashing
EP1073721B1 (de) 1998-04-22 2005-08-31 Genvec, Inc. Effiziente reinigung von adenovirus

Also Published As

Publication number Publication date
AU774437B2 (en) 2004-06-24
JP2011120596A (ja) 2011-06-23
CA2364934C (fr) 2011-10-18
JP2002536992A (ja) 2002-11-05
US7264958B1 (en) 2007-09-04
EP1155120A1 (de) 2001-11-21
CA2364934A1 (fr) 2000-08-31
DE60029195D1 (de) 2006-08-17
EP1155120B1 (de) 2006-07-05
AU2811800A (en) 2000-09-14
JP4802366B2 (ja) 2011-10-26
DE60029195T2 (de) 2007-06-28
WO2000050573A1 (fr) 2000-08-31

Similar Documents

Publication Publication Date Title
DE60029195D1 (de) Verfahren zur gewinnung von purifizierter virenzuammensetzung
ATE324436T1 (de) Verfahren zur reinigung von menschlichen, dem papillomavirus ähnlichen partikeln.
ATE306252T1 (de) Verfahren zur herstellung kristalliner partikel zur inhalation
ATE278785T1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
ATE322252T1 (de) Verfahren zur herstellung und sammlung von kristallinen partikeln
DE60114348D1 (de) Verfahren zur Reinigung von Gasen
DE60221619D1 (de) Verfahren zur Reinigung von Synthesegas
DE69637509D1 (de) Verfahren zur reinigung von faktor-ix
DE69908998D1 (de) Verfahren zur Herstellung von Kohlenstoff
DE69703957D1 (de) Verfahren zur Herstellung von kristallinen Ceroxidteilchen.
AU1811301A (en) Methods for removal, purification, and concentration of viruses, and methods of therapy based thereupon
DE59800264D1 (de) Verfahren zur Herstellung von SiO2-Granulat
DE60212062D1 (de) Verfahren zur Herstellung von porösen Polyesterpartikeln
ATE449104T1 (de) Verfahren zur reinigung von fibrinogen
DE60203975D1 (de) Verfahren zur Herstellung von magnetischen Teilchen, magnetische Teilchen und magnetischer Werkstoff
ATE268749T1 (de) Verfahren zur herstellung von iopamidol
AU2003279240A1 (en) Methods for purifying viral particles for gene therapy
ATE509889T1 (de) Verfahren zur herstellung von granulatförmigem umhüllten natriumpercarbonat und verfahrensgemäss erhältliches produkt
DE60032077D1 (de) Verfahren zur dehalogenierung von kohlenwasserstoffhaltigen kohlenstoff-kohlenstoff doppelbindungen
DE60002020D1 (de) Verfahren zur Herstellen von hochreinem Xylitol
DE69616385D1 (de) Methode zur reinigung von prozessgasen
AU2003265052A1 (en) Process for the purification of recombinant proteins from complex media and purified proteins obtained thereby
WO2003093431A3 (en) Ablated slam-dependent entry
DE59912502D1 (de) Verfahren zur herstellung von enantiomerenreinem n-methyl- n- (1s)- 1-phenyl- 2-((3s)-3- hydroxypyrrolidin- 1-yl)ethyl]- 2,2- diphenylacetamid
DE19983485T1 (de) Verfahren zur Herstellung von Gasfedern

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1155120

Country of ref document: EP